Free Trial

First Tracks Biotherapeutics (TRAX) 10K Form and Latest SEC Filings 2026

$18.16 -0.27 (-1.47%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$17.52 -0.64 (-3.50%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest First Tracks Biotherapeutics SEC Filings & Recent Activity

First Tracks Biotherapeutics (NASDAQ:TRAX) has submitted 41+ documents to the U.S. Securities and Exchange Commission (SEC) since 2026. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 424B3 submitted on May 14, 2026.

Form 4
First Tracks Biotherapeutics, Inc. Reports Ownership Change on May. 14, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
First Tracks Biotherapeutics Files Current Report on Apr. 20, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
First Tracks Biotherapeutics Files Quarterly Report on May. 14, 2026

The 10-Q contains First Tracks Biotherapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

First Tracks Biotherapeutics SEC Filing History

Browse First Tracks Biotherapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/14/2026 4:12 PM
First Tracks Biotherapeutics (2091349) Filer
Form 424B3
05/14/2026 3:32 PM
First Tracks Biotherapeutics (2091349) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/14/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Lizzul Paul F. (1711462) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Tamboli Ajim (1855684) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:05 PM
Faga Daniel (1673528) Reporting
First Tracks Biotherapeutics (2091349) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
STONE BENJAMIN (2128786) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:05 PM
FENTON DENNIS M (1184627) Reporting
First Tracks Biotherapeutics (2091349) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Orwin John A (1477384) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Jain Rita (1707797) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Schmid John P. (1478916) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Marquet Magda (1631486) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
Trump's gold order: the announcement they won't put on the front page (Ad)

On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel

Request the free guide in 30 seconds and get positioned now
05/14/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Ware J. Anthony (1715429) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 11:15 PM
First Tracks Biotherapeutics (2091349) Filer
Form EFFECT
04/23/2026 5:08 PM
First Tracks Biotherapeutics (2091349) Issuer
Tamboli Ajim (1855684) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/23/2026 5:08 PM
First Tracks Biotherapeutics (2091349) Issuer
Tamboli Ajim (1855684) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 4:07 PM
EcoR1 Capital, LLC (1587114) Reporting
First Tracks Biotherapeutics (2091349) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 4:09 PM
EcoR1 Capital, LLC (1587114) Filed by
First Tracks Biotherapeutics (2091349) Subject
Form SCHEDULE 13G
04/22/2026 4:07 PM
EcoR1 Capital, LLC (1587114) Reporting
First Tracks Biotherapeutics (2091349) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/22/2026 3:19 PM
First Tracks Biotherapeutics (2091349) Issuer
STONE BENJAMIN (2128786) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/22/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Marquet Magda (1631486) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:05 PM
Faga Daniel (1673528) Reporting
First Tracks Biotherapeutics (2091349) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:05 PM
ANAPTYSBIO, INC (1370053) Reporting
First Tracks Biotherapeutics (2091349) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Jain Rita (1707797) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:05 PM
FENTON DENNIS M (1184627) Reporting
First Tracks Biotherapeutics (2091349) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Orwin John A (1477384) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Schmid John P. (1478916) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Ware J. Anthony (1715429) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:05 PM
First Tracks Biotherapeutics (2091349) Issuer
Lizzul Paul F. (1711462) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:23 PM
First Tracks Biotherapeutics (2091349) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2026 4:02 PM
First Tracks Biotherapeutics (2091349) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
04/01/2026 3:38 PM
First Tracks Biotherapeutics (2091349) Issuer
Jain Rita (1707797) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 3:38 PM
First Tracks Biotherapeutics (2091349) Issuer
Ware J. Anthony (1715429) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 3:31 PM
ANAPTYSBIO, INC (1370053) Reporting
First Tracks Biotherapeutics (2091349) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 3:33 PM
Faga Daniel (1673528) Reporting
First Tracks Biotherapeutics (2091349) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 3:34 PM
First Tracks Biotherapeutics (2091349) Issuer
Lizzul Paul F. (1711462) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 3:34 PM
First Tracks Biotherapeutics (2091349) Issuer
Orwin John A (1477384) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 3:35 PM
First Tracks Biotherapeutics (2091349) Issuer
Marquet Magda (1631486) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 3:36 PM
FENTON DENNIS M (1184627) Reporting
First Tracks Biotherapeutics (2091349) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 3:37 PM
First Tracks Biotherapeutics (2091349) Issuer
Schmid John P. (1478916) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 2:36 PM
First Tracks Biotherapeutics (2091349) Filer
Form CERT
03/27/2026 3:31 PM
First Tracks Biotherapeutics (2091349) Filer
Form 10-12B/A
Millionaire warns: Move your money before May 15 (Ad)

Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2025 - says Trump's installation of a new Federal Reserve chair is triggering the most significant shift in U.S. markets in nearly 20 years. When the Fed cut rates in 2020, his readers had a chance at 62% gains. A 2022 rate-hike signal produced 117% in under a month. Now Benedict has identified the single ticker he believes will be at the center of the coming money flows - and he's revealing it free before May 15.tc pixel

Click here to see the one ticker Larry Benedict is recommending now
(Data available from 1/1/2016 forward)

First Tracks Biotherapeutics SEC Filings - Frequently Asked Questions

First Tracks Biotherapeutics (TRAX) has submitted 41+ filings to the SEC since 2026. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 424B3 submitted on May 14, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:TRAX) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners